Search for: "MERCK & CO., INC. "
Results 41 - 60
of 674
Sort by Relevance
|
Sort by Date
21 Sep 2020, 12:41 pm
Johnson & Johnson-Merck Consumer Pharm. [read post]
18 Jun 2020, 2:24 pm
” Various drug manufacturers, including Merck & Co., Inc., Eli Lilly and Company, and Amgen Inc., were joined by the Association of National Advertisers, Inc. in challenging the rule in June 2019. [read post]
1 May 2020, 7:14 am
Merck & Co., Inc., April 27, 2020, Pratter, G.). [read post]
30 Apr 2020, 3:30 am
Merck & Co., 46 USPQ2d 1478, 1479 (TTAB 1998) (citing Eurostar Inc. v. [read post]
20 Feb 2020, 6:33 am
Merck & Co., the Third Circuit held that plaintiffs who opt out of a securities class action are not precluded under the Securities Litigation Uniform Standards Act of 1998 (SLUSA) from bringing state law fraud claims in follow-on individual actions, even if federal claims are time-barred. [read post]
29 Nov 2019, 9:05 pm
Silliker Lecture was established by Silliker Inc. [read post]
27 Nov 2019, 3:33 am
Cir. 2015); seealso KSR Int’l Co. v. [read post]
8 Nov 2019, 1:32 pm
Merck & Co., 46 USPQ2d 1478 (TTAB 1998). [read post]
3 Oct 2019, 11:01 am
Merck & Co, Inc., No. 18-2317, 2019 WL 4309663, 2019 U.S. [read post]
27 Sep 2019, 2:49 am
”); Merck & Co. v. [read post]
11 Sep 2019, 1:00 pm
The specific DP IV inhibitor sitagliptin as such, however, is not identified in Royalty Pharma’s basic patent as it was developed only after the filing date of the patent (and gave rise to a distinct patent filed by Merck & Co., Inc.). [read post]
30 Aug 2019, 6:31 am
Interestingly, Canadian courts used to follow the British approach but, in its recent decision in Merck & Co. v. [read post]
24 Jul 2019, 6:22 am
Legal background regarding Arrow-declarations The underlying jurisdiction was established in Arrow Generics v Merck & Co Inc [2007] FSR 39 and approved by the Court of Appeal in Fujifilm v AbbVie [2017] EWCA Civ. 1. [read post]
27 Jun 2019, 6:15 am
Patent 6,881,745 over its objection that the petition for inter partes review (IPR) filed by Merck Sharpe & Dohme (MSD) was fatally defective for having omitted parent corporation Merck & Co., Inc. as a real-party-in-interest. [read post]
27 Jun 2019, 6:15 am
Patent 6,881,745 over its objection that the petition for inter partes review (IPR) filed by Merck Sharpe & Dohme (MSD) was fatally defective for having omitted parent corporation Merck & Co., Inc. as a real-party-in-interest. [read post]
25 Jun 2019, 9:45 pm
(here) the Petitioner failed to identify Merck & Co., Inc. [read post]
23 Jun 2019, 7:46 pm
Here’s the timeline: May 29, 2015, Mayne sued both Merck & Co, Inc. [read post]
14 Jun 2019, 7:33 am
Congratulated by EPA Assistant Administrator Alexandra Dapolito Dunn, the 2019 awardees included: Academic Award -- Professor Sanjoy Banerjee, The City University of New York – Energy Institute, Rechargeable Alkaline Zn-MnO2 Batteries for Grid Storage Applications; Small Business Award -- Kalion, Inc., Microbially Produced High-Purity Glucaric Acid for Diverse Uses; Greener Synthetic Pathways Award -- Merck & Co., Innovating for a Greener… [read post]
30 May 2019, 8:02 am
Merck & Co., Inc. [read post]
29 May 2019, 9:26 am
For example, a similar incident called NotPetya caused Mondelez International, Inc., and Merck & Co. damages of approximately $100 million and $700 million, respectively – and, according to multiple sources, EternalBlue was a culprit in NotPetya also. [read post]
